ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial.
about
Role of "Western diet" in inflammatory autoimmune diseasesPharmacological Approaches to Delaying Disability Progression in Patients with Multiple SclerosisEnvironmental factors in autoimmune diseases and their role in multiple sclerosisVitamin D as a clinical biomarker in multiple sclerosisAlpha-tocopherol and MRI outcomes in multiple sclerosis--association and predictionDisease Type- and Status-Specific Alteration of CSF Metabolome Coordinated with Clinical Parameters in Inflammatory Demyelinating Diseases of CNSNotes on the epidemiology of multiple sclerosis, with special reference to dietary habits.Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activityDietary Interventions in Multiple Sclerosis: Development and Pilot-Testing of an Evidence Based Patient Education Program.Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: The EnvIMS study.Untargeted Plasma Metabolomics Identifies Endogenous Metabolite with Drug-like Properties in Chronic Animal Model of Multiple SclerosisFish and egg specific immunoglobin e in multiple sclerosis patients.Efficacy of fish oil on serum of TNF α , IL-1 β , and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b.No association of tobacco use and disease activity in multiple sclerosisAnti-inflammatory nutritional intervention in patients with relapsing-remitting and primary-progressive multiple sclerosis: A pilot studyAssociation of fish consumption and Ω 3 supplementation with quality of life, disability and disease activity in an international cohort of people with multiple sclerosis.Polyunsaturated fatty acids in multiple sclerosis therapy.The Deleterious Effects of Oxidative and Nitrosative Stress on Palmitoylation, Membrane Lipid Rafts and Lipid-Based Cellular Signalling: New Drug Targets in Neuroimmune Disorders.The role of diet in multiple sclerosis: A review.Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010-2015.The influence of sodium on pathophysiology of multiple sclerosis.Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients.Polyunsaturated fatty acids and the risk of multiple sclerosis.Modulation of Multiple Sclerosis and Its Animal Model Experimental Autoimmune Encephalomyelitis by Food and Gut Microbiota.Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis.Neurofilament light chain predicts disease activity in relapsing-remitting MS.Combination treatment of docosahexaenoic acid (DHA) and all-trans-retinoic acid (ATRA) inhibit IL-17 and RORγt gene expression in PBMCs of patients with relapsing-remitting multiple sclerosis.A need for national registries and international collaborative research in multiple sclerosis.Interrelation of Diet, Gut Microbiome, and Autoantibody Production.Vitamin A: yet another player in multiple sclerosis pathogenesis?Longitudinal Associations of Modifiable Lifestyle Factors With Positive Depression-Screen Over 2.5-Years in an International Cohort of People Living With Multiple SclerosisThe Role of Diet in Multiple Sclerosis: Mechanistic Connections and Current Evidence
P2860
Q26996114-C4B6410F-6E44-4CE1-A67C-A28BBBEADEB1Q27000269-E7298BC2-5B60-429E-BA07-9147C498EAD3Q28078461-81A5E20F-EF16-4B1B-82EC-05A6B1CAA92DQ28287015-57B56912-541E-4761-ABC7-B8088B4F5E02Q28485223-82724BE2-5960-47ED-89FB-B9A59B4325B6Q28553584-DB286208-BF8E-49A9-A4B9-1BE398CE534FQ34039982-75EC6363-B50C-4EEF-9976-D001BDEFFC17Q34999439-8F0D3311-218D-42FE-972B-EB39B2FD8884Q36169584-A16676CF-1D78-407E-A386-E2B313033E91Q36311036-A013BD5B-8209-495B-8FFA-34CD62C36D7BQ36407218-2546013C-9ABF-4275-82BA-35A4D9E608ABQ36917709-E516CDC6-C389-440D-BF22-6558771094A4Q36989834-4F7EEDD9-5CF8-4CC0-9D06-3F9494B141BDQ37098475-3A62C3BF-CAE8-43AB-8774-46BF317D2C24Q37107063-2F2B8CBE-626C-4239-B1C4-E5BFE8277922Q37290620-C0A2B1FA-79F8-44CC-A772-A3775F48A018Q38070775-D6D37834-26F7-4A0D-BA4E-B036E2417978Q38574561-C907FEEB-D177-4095-9B4F-A54BA6B5270FQ38740469-6CE3EAD7-028A-4B0B-AEA7-661773CB7F56Q38801807-F953E3A3-6FA7-454A-A222-5118F45BBCECQ39081430-FDA5DA4D-56A2-4DAE-B5BF-F3A72B8CB8C3Q39902201-BC2FDD0D-F029-4850-942E-CE0391311513Q40352148-F63E4CA8-DE27-4768-86FE-818C55DAC1A3Q41453198-6BCE7E92-C72A-4C47-9917-735D84971CE3Q42217719-7D3D0D9E-AFFD-448D-9113-566D646462F8Q47138197-1157F6FE-127C-4BE1-AB6C-D25BA3230C05Q48271530-4F01650D-B5BD-4B01-8784-C839E4BAEBCAQ53118212-20B55582-955F-47AF-B617-FC6CF6B4A485Q55043186-CE3D35C4-B578-48DF-BBAF-477EBF92B179Q57911740-9E3A1629-30C9-44B9-8628-53BFA893B53DQ58693787-71DD0F9B-9A8A-4803-9D7E-9802019D7EDEQ58772726-15B21CD0-E2A0-4D24-A404-02D25C94D4E9
P2860
ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
ω-3 fatty acid treatment in mu ...... ind, placebo-controlled trial.
@en
type
label
ω-3 fatty acid treatment in mu ...... ind, placebo-controlled trial.
@en
prefLabel
ω-3 fatty acid treatment in mu ...... ind, placebo-controlled trial.
@en
P2093
P921
P1433
P1476
ω-3 fatty acid treatment in mu ...... ind, placebo-controlled trial.
@en
P2093
Antonie G Beiske
Bård Bjørnarå
Finn Lilleås
Frøydis Dalene
Grethe Kleveland
Harald Hovdal
Inge Christoffer Olsen
Jan Schepel
Kristian S Bjerve
Oivind Torkildsen
P304
P356
10.1001/ARCHNEUROL.2012.283
P577
2012-08-01T00:00:00Z